➡️➡️Shelter Pharma Limited:
📌Recent Board Meeting Update:-
▪️FY24H1 Revenue: 19.31Cr🔥(FY23H1 Rev:17Cr)
▪️FY24H1 PAT: 3.1Cr🔥(FY23H1 PAT:2.4Cr)
▪️P/E:10✅(Annualized)
▪️Cash equivalent:Rs.4.12Cr
▪️Debt:0.45Cr
▪️Reserves and Surplus:21Cr
📌Shelter Pharma Limited has received official approvals to export for premium range of nutraceutical products to the Kuwait market✅.
📌Shelter Pharma Limited secured a noteworthy order from Berlin International Medicines(KUWAIT), Equipment & Devices Trading Co. W.L.L for the product of D3 Cure 50ml and Ferrocure Capsule 3x10 worth Rupees 75 lakhs approximately.
📌Shelter Pharma also has presence in various other countries like: Egypt ,Kuwait, Qatar, Romania, UAE, Bangladesh, Nepal, Cameroon, Iraq, Yemen.
📌📌Prominent Clients : Gujarat Co. op. Milk Marketing Federation Limited (AMUL), Government Undertakings
📌📌 ➡️ ➡️
▪️Incorporated in 2007, Shelter Pharma Limited✅, previously known as Shelter Pharmacy, is engaged in the business of manufacturing herbal products in Human Pharma as well as the Veterinary space.
▪️The company manufactures herbal medicines that cover veterinary, poultry, and human health care. Headquartered in Himmatnagar, Gujarat, the aim of the company is to offer cost-effective and superior solutions to the health problems of humans and animals.
▪️There is a comprehensive range of health supplements offered by the company for the betterment of humans and poultry. Ayurveda meets modernity - This is the driving force behind the company.
▪️Shelter Pharma's product list includes Human Healthcare products such as Lemonade Barley Water, Sherolax, Baldeepak, and Stonyl Tablets and Veterinary Healthcare products such as Agrical Powder, Lactocal gel, Shelodex Ultra Ointment.
▪️Shelter clientele comes from rural/semi-urban markets.
▪️The company sources its raw materials i.e. herbal plants from the nearby regions and markets them in rural/semi-urban areas with price-competitive quality remedies. The company is marketing its products under "Shelter" brand.
📌📌
▪️IPO price: Rs.42
▪️IPO size:16.03 CR
▪️CMP:Rs.56
▪️Market cap:65 CR
▪️P/E:10 ✅
▪️EPS:5.36 (annualized)
▪️52 Wk High:62.9
▪️52 Wk Low:37.5
▪️RoNW:39.86%
▪️Debt/Equity:~0
▪️Assets:34.56
▪️Total Borrowing:0.45Cr (Reserves and Surplus:21Cr)
▪️Share Holding Pre Issue:84.92%
▪️Share Holding Post Issue:56.89%
📌FINANCIALS:
▪️FY23 revenue is 36.15 CR as compared to 30 CR(FY22),21%✅ growth yoy.
▪️FY23 PAT is 5.78 CR as compared to 1.83 CR(FY22), 215%✅ growth yoy.
▪️60% growth in revenue in last 2 years.
▪️578%🔥 growth in PAT in last 2 years.
📌IPO funds:
from the net proceedings, it will utilize Rs. 14.00 cr. for working capital, and Rs. 0.88 cr. for general corporate purposes.
📌PEERS:
As per the offer document, company has shown Dabur India and Emami Ltd. as their listed peers. They are currently trading at a P/E of 55, and 31. However, they are not truly comparable on an apple-to-apple basis.
📌SECTOR GROWTH:
▪️ The Ayurveda sector in India reached US$ 4.4 billion by 2018 end and grow at 16% CAGR until 2025✅.
▪️ In November 2020, Prime Minister Mr. Narendra Modi dedicated two future-ready national premier Ayurveda institutions to the country to mark celebrations of the 5th Ayurveda Day’.Also, World Health Organisation (WHO) announced the setting up of the Global Centre of Traditional Medicine in India.
▪️Indian pharmaceutical industry is expected to reach ~US$ 130 billion by 2030.
▪️India ranks 3rd worldwide for pharmaceutical production by volume and 14th by value. The country has an established domestic pharmaceutical industry, with a strong network of 3,000 drug companies and ~10,500 manufacturing units.
▪️In July 2021, the Union Cabinet approved continuation of the National Ayush Mission, responsible for the development of traditional medicines in India, as a centrally sponsored scheme until 2026.
📌STRENGTH:
➢Experienced Promoters and Management Team.
➢Scalable Business Model.
➢Wide and diverse range of product offerings.
➢Marketing & Branding Efforts.
📌FUTURE PLAN:
▪️Focus on Increase in Volume of Sales.
▪️Increasing the number of Clients.
▪️Building-up as a Professional Organisation.
▪️Continue to attract and retain talent.
Credits: @SaurabhJ1999
📌Disclosure: Not a buy recommendation. Only for study and education purpose. Please consult your financial advisor before investing.
📌Recent Board Meeting Update:-
▪️FY24H1 Revenue: 19.31Cr🔥(FY23H1 Rev:17Cr)
▪️FY24H1 PAT: 3.1Cr🔥(FY23H1 PAT:2.4Cr)
▪️P/E:10✅(Annualized)
▪️Cash equivalent:Rs.4.12Cr
▪️Debt:0.45Cr
▪️Reserves and Surplus:21Cr
📌Shelter Pharma Limited has received official approvals to export for premium range of nutraceutical products to the Kuwait market✅.
📌Shelter Pharma Limited secured a noteworthy order from Berlin International Medicines(KUWAIT), Equipment & Devices Trading Co. W.L.L for the product of D3 Cure 50ml and Ferrocure Capsule 3x10 worth Rupees 75 lakhs approximately.
📌Shelter Pharma also has presence in various other countries like: Egypt ,Kuwait, Qatar, Romania, UAE, Bangladesh, Nepal, Cameroon, Iraq, Yemen.
📌📌Prominent Clients : Gujarat Co. op. Milk Marketing Federation Limited (AMUL), Government Undertakings
📌📌 ➡️ ➡️
▪️Incorporated in 2007, Shelter Pharma Limited✅, previously known as Shelter Pharmacy, is engaged in the business of manufacturing herbal products in Human Pharma as well as the Veterinary space.
▪️The company manufactures herbal medicines that cover veterinary, poultry, and human health care. Headquartered in Himmatnagar, Gujarat, the aim of the company is to offer cost-effective and superior solutions to the health problems of humans and animals.
▪️There is a comprehensive range of health supplements offered by the company for the betterment of humans and poultry. Ayurveda meets modernity - This is the driving force behind the company.
▪️Shelter Pharma's product list includes Human Healthcare products such as Lemonade Barley Water, Sherolax, Baldeepak, and Stonyl Tablets and Veterinary Healthcare products such as Agrical Powder, Lactocal gel, Shelodex Ultra Ointment.
▪️Shelter clientele comes from rural/semi-urban markets.
▪️The company sources its raw materials i.e. herbal plants from the nearby regions and markets them in rural/semi-urban areas with price-competitive quality remedies. The company is marketing its products under "Shelter" brand.
📌📌
▪️IPO price: Rs.42
▪️IPO size:16.03 CR
▪️CMP:Rs.56
▪️Market cap:65 CR
▪️P/E:10 ✅
▪️EPS:5.36 (annualized)
▪️52 Wk High:62.9
▪️52 Wk Low:37.5
▪️RoNW:39.86%
▪️Debt/Equity:~0
▪️Assets:34.56
▪️Total Borrowing:0.45Cr (Reserves and Surplus:21Cr)
▪️Share Holding Pre Issue:84.92%
▪️Share Holding Post Issue:56.89%
📌FINANCIALS:
▪️FY23 revenue is 36.15 CR as compared to 30 CR(FY22),21%✅ growth yoy.
▪️FY23 PAT is 5.78 CR as compared to 1.83 CR(FY22), 215%✅ growth yoy.
▪️60% growth in revenue in last 2 years.
▪️578%🔥 growth in PAT in last 2 years.
📌IPO funds:
from the net proceedings, it will utilize Rs. 14.00 cr. for working capital, and Rs. 0.88 cr. for general corporate purposes.
📌PEERS:
As per the offer document, company has shown Dabur India and Emami Ltd. as their listed peers. They are currently trading at a P/E of 55, and 31. However, they are not truly comparable on an apple-to-apple basis.
📌SECTOR GROWTH:
▪️ The Ayurveda sector in India reached US$ 4.4 billion by 2018 end and grow at 16% CAGR until 2025✅.
▪️ In November 2020, Prime Minister Mr. Narendra Modi dedicated two future-ready national premier Ayurveda institutions to the country to mark celebrations of the 5th Ayurveda Day’.Also, World Health Organisation (WHO) announced the setting up of the Global Centre of Traditional Medicine in India.
▪️Indian pharmaceutical industry is expected to reach ~US$ 130 billion by 2030.
▪️India ranks 3rd worldwide for pharmaceutical production by volume and 14th by value. The country has an established domestic pharmaceutical industry, with a strong network of 3,000 drug companies and ~10,500 manufacturing units.
▪️In July 2021, the Union Cabinet approved continuation of the National Ayush Mission, responsible for the development of traditional medicines in India, as a centrally sponsored scheme until 2026.
📌STRENGTH:
➢Experienced Promoters and Management Team.
➢Scalable Business Model.
➢Wide and diverse range of product offerings.
➢Marketing & Branding Efforts.
📌FUTURE PLAN:
▪️Focus on Increase in Volume of Sales.
▪️Increasing the number of Clients.
▪️Building-up as a Professional Organisation.
▪️Continue to attract and retain talent.
Credits: @SaurabhJ1999
📌Disclosure: Not a buy recommendation. Only for study and education purpose. Please consult your financial advisor before investing.
Loading suggestions...